Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?
- 1 January 2004
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (1), 7-10
- https://doi.org/10.1200/jco.2004.10.907
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Adjuvant therapy of cutaneous melanoma: the interferon debateAnnals of Oncology, 2003
- Malignant melanoma: current state of primary and adjuvant treatmentCritical Reviews in Oncology/Hematology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trialThe Lancet, 2001
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001
- Adjuvant interferon alpha 2b in high risk melanoma – the Scottish studyBritish Journal of Cancer, 2001
- High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801Journal of Clinical Oncology, 2001
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996